According to Straits Research, the global myocardial infarction market size was valued at $2.61 billion in 2025 and is projected to grow from $2.82 billion in 2026 to $5.22 billion by 2034 at a CAGR of 8% during the forecast period 2026-2034. Myocardial Infarction or heart attack is a condition when blood flow at a heart muscle stops or decreases. The condition may occur due to various reasons, including excessive smoking, unhealthy food habits and others. It is more common in elderly people and may lead to death. Surgery, different drug classes and types, and other treatments are available for the condition. All the treatment methods may differ from individual to individual. High chances of reoccurrence are the major factors leading to the increasing usage of the prevention and treatment drugs. Increasing research and development activities for safe drug development Increasing research and development activities and growing technological advancements by various companies and government organizations are creating lucrative opportunities for market players. Various companies are emphasizing on developing innovative drugs. For instance, Novartis has developed a drug called canakinumab (ACZ885). It helps to prevent heart attacks by controlling inflammation—a different approach than lowering cholesterol level. According to Novartis, it reduced the cardiovascular risk by 25% in the trial presented at American Heart Association Session 2017. Asia Pacific is the fastest growing region in the forecast period Myocardial infarction is one of the major diseases in China. It has become the major cause of an emergency over the past few decades owing to changing lifestyle and declining physical activity. In China, of men aged 30–44 years who die from cardiovascular disease, 46% of these deaths are attributable to tobacco. Additionally, there are more than 300 million smokers in China, nearly one-third of the world's total smoking population. This is projected to increase the risk of developing cardiovascular diseases, which is also expected to increase the demand for their demand. Thus, China is projected to witness considerable growth in the market during the forecast period. Market Segments By Product Type Analgesics Antiplatelet agents Vasodilators Thrombolytics and anti-thrombotic agents Glycoprotein IIb/IIIa inhibitors Β adrenergic blockers Angiotensin receptor antagonists Angiotensin converting enzyme inhibitors By Distribution channel Hospitals Hospital Pharmacies Drug Stores Online drug stores Regions Covered America North America U.S. Canada Mexico South America Europe Western Europe UK Germany France Italy Spain Rest of Europe Eastern Europe Asia-Pacific China India Japan South Korea Australia Rest of Asia-Pacific Middle East Saudi Arabia UAE Qatar Rest of The Middle East Africa South Africa Ghana Nigeria